Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis

BACKGROUND: Standard of care for bleed prevention in patients with severe congenital hemophilia A is continuous prophylaxis with factor VIII (FVIII), typically administered intravenously 2-3 times per week in the home setting. Nonfactor prophylaxis and gene therapy are emerging novel prophylaxis str...

Descripción completa

Detalles Bibliográficos
Autores principales: Croteau, Stacy E, Cook, Keziah, Sheikh, Lamiya, Chawla, Anita, Sammon, Joshua, Solari, Paul, Kim, Benjamin, Hinds, David, Thornburg, Courtney D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391018/
https://www.ncbi.nlm.nih.gov/pubmed/33645244
http://dx.doi.org/10.18553/jmcp.2021.27.3.316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391018/
https://www.ncbi.nlm.nih.gov/pubmed/33645244
http://dx.doi.org/10.18553/jmcp.2021.27.3.316

Ejemplares similares